Clinical Trial Update: A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and immune response of two-dose Shigella vaccine in Kenyan adults. The study is completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Shigella vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Shigella Sonnei Infection | Phase 2 | Status: COMPLETED | Results posted: 2019-02-18